Advances in Treatment Options for Early-Stage NSCLC

Julia K. Rotow, MD

Disclosures

September 07, 2022

Julia K. Rotow, MD, outlines some major areas where advances are needed in the management of patients with early-stage non–small cell lung cancer (NSCLC). First, she anticipates that immunotherapies and targeted therapies available in the metastatic setting will become available as personalized therapy for patients in the early-stage setting.

Additionally, Dr Rotow looks at tools such as cell-free DNA technology that are starting to show some ability to better assess treatment response and disease progression in patients with early-stage NSCLC. She looks to a future where more dynamic options are available in the neoadjuvant setting for patients with early-stage NSCLC to better tailor therapy and improve long-term outcomes.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....